International Complement Workshop News Today

-- First-In-Human Single Ascending Dose Clinical Data for RLYB116 Demonstrated a Reduction in Free C5 Greater than 99% at 24 Hours for the 100 mg dose and at 12, 24, and 72 Hours for the 300 mg dose in Healthy Participants ---- Mean Estimated Elimination Half-Life for RLYB116 was > 300 Hours ---- No Severe or Seriou...

-- RLYB212 Phase 1b Proof-of-Concept Study Results Presented at the 31st Congress of the International Society of Thrombosis and Haemostasis in June 2023 -- -- RLYB212 Phase 1 Multiple Dose Cohort...